|
|
News Breaks
|
November 17, 2009
|
| 13:55 EDT |  | PRX |
| theflyonthewall.com: | Par Pharmaceutical volatility low into PDUFA events | | Par Pharmaceutical is recently up 55c to $23.89. Par's Zuplenz has a February 2010 PDUFA and miconazole MBT an April 2010 PDUFA. PAR December option implied volatility is at 45, January is at 42, May is at 45; below its 26-week average of 52, according to Track Data, suggesting decreasing price movement. :theflyonthewall.com |
|
|
News For PRX From The Last 14 Days Check below for free stories on PRX the last two weeks.
There are 2 items on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing. |
|
February 8, 2012
|
| 09:29 EDT |  | PRX |
| theflyonthewall.com: | Intellipharmaceutics targeting 2012 FDA approval of generic Focalin XR | | Intellipharmaceutics' (IPCI) goals for 2012 include: Obtain FDA approval of Intellipharmaceutics' generic version of Focalin XR; File two additional ANDAs with the FDA; Establish additional development/marketing alliances; Schedule a pre-IND meeting with FDA to discuss Rexista oxycodone clinical development plan; Complete manufacturing of clinical batches of Rexista oxycodone; and Initiate Phase I studies using clinical batches of Rexista oxycodone. Note that Intellipharmaceutics' in February the company completed private placement financing, and revenue from the amendment of the existing development and commercialization agreement between the Company and Par Pharmaceutical (PRX) to include additional strengths of Focalin XR generic products. Under the terms of the expanded agreement, Intellipharmaceutics received a cash payment from Par and will continue to receive a share of profits from any future sales of our generic versions of Focalin XR. :theflyonthewall.com |
|
|
February 3, 2012
|
| 06:18 EDT | | PRX |
|
|
|
|
|
Subscribe for More Information